ArticlePloS one2024
Exploring consumer preferences for cannabis edible products to support public health policy: A discrete choice experiment.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Relative Preference of Cannabis, Alcohol, and Nicotine Products Among U.S. Adolescents and Young Adults Who Are Using or Susceptible to Cannabis Use: Insights from a Best-Worst Scaling Study.Substance use & misuse · 2026Article
- Behavioral and Self-Report Cognitive Impairment Differences between Fast-Acting, Standard, and Placebo Cannabis Edibles.Research square · 2026Article
- Preferences and Willingness to Pay for Smart Bracelets Among Chinese Pregnant and Postpartum Women: Discrete Choice Experiment.Journal of medical Internet research · 2026Article
- An update on cannabis products, cannabinoid content, plant type, and prices five years after legalization in Ontario, Canada.Journal of cannabis research · 2026Article
- Exploring pain management preferences: a discrete choice experiment on cannabis or opioids among middle-aged and older adults.Journal of health, population, and nutrition · 2025Article
- Patterns of Cannabis Use among Women With HIV in the United States.AIDS and behavior · 2025Article
- Multilevel determinants of cannabis prices in legal markets: Evidence from products sold in nearly 4000 cannabis dispensaries in the United States.The International journal on drug policy · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn October 2019, cannabis edibles were legalized for sale in Canada for non-medical use. This move was intended to improve public safety by regulating contents (including a maximum 10 mg tetrahydrocannabinol (THC) per package) and packaging to prevent accidental ingestion or over consumption. This study aimed to explore consumer preferences for cannabis edibles to inform cannabis policy.
methodsWe explored the relative importance and trade-offs consumers make for attributes of cannabis edibles using a discrete choice experiment. Attributes included type of edible, price, THC content, cannabis taste, package information, product consistency, product recommendations, and Health Canada regulation. Participants lived in Canada, were 19 years of age or older, and purchased a cannabis edible in the last 12 months. A multinomial logit (MNL) model was used for the base model, and latent class analysis to assess preference sub-groups. This study was approved by the institutional ethics committee.
resultsAmong 684 participants, the MNL model showed that potency was the most relevant attribute, followed by edible type. A two-group latent class model revealed two very distinct preference patterns. Preferences for group 1 (~65% of sample) were driven primarily by edible type, while for group 2 (~35% of sample) were driven almost entirely by THC potency.
conclusionThis study found that consumer preferences for ~65% of consumers of cannabis edibles are being met through regulated channels. The remaining ~35% are driven by THC potency at levels that are not currently available on the licensed market. Attracting this market segment will require reviewing the risks and benefits of restricting THC package content.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.